Tracked deals
1151
1151 tracked deals across 2007-2026.
Tracked deals
1151
1151 tracked deals across 2007-2026.
Buyer mix
Mixed buyer set
881 strategic · 567 pe
Top trend
Volume peaked in 2021
223 tracked deals announced in 2021.
Primary Insight
Build a buyer list for your Medical Devices deal
Find buyers actively acquiring medical devices companies.
Find buyers like these for your dealBuyer Snapshot
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Boston Scientific Corporation | 16 | Global medical technology company developing and commerci... | Strategic |
| ARCHIMED | 14 | European private equity investor focused exclusively on h... | PE |
| Healthcare Holding Schweiz AG | 12 | Buy, Build & Technologize platform and leading provider/d... | Strategic (PE-backed) |
| Arcline Investment Management | 11 | Growth-oriented private equity firm investing in niche, m... | PE |
| Audax Private Equity | 11 | Middle-market private equity firm focused on buy-and-buil... | PE |
| Calibre Scientific | 11 | Diversified global provider of life science reagents, too... | Strategic |
| Linden Capital Partners | 10 | Chicago-based private equity firm focused exclusively on ... | PE |
| Ampersand Capital Partners | 9 | Middle-market private equity firm focused on growth-orien... | PE |
| Stryker | 9 | Global medical technologies company offering MedSurg, Neu... | Strategic |
| ARCH Medical Solutions Corp. | 8 | Precision-manufacturing platform specializing in cutting ... | Strategic (PE-backed) |
Last 10 years
Supporting Data
Stryker agreed to invest approximately $400 million in CMR Surgical through preferred equity, with an exclusive option to acquire the company’s remaining equity in the future. The strategic alliance also makes Stryker the exclusive U.S. sales agent for CMR’s Versius portfolio, while CMR retains product development and commercialization outside the United States.
STERIS Corporation, a wholly owned subsidiary of STERIS plc, signed a definitive agreement to acquire all outstanding equity of Xodus Medical and certain related affiliates for $2.1 billion at closing, with potential earnout consideration of up to $150 million. The acquisition is expected to expand STERIS’s healthcare consumables portfolio, particularly operating-room products, and is anticipated to close by December 31, 2026, subject to customary conditions and regulatory approvals.
Trace Medical acquired a majority interest in LiViliti Health Products, building on an existing strategic investment between the companies. The deal combines Trace Medical’s nationwide distribution and biomedical servicing network with LiViliti’s respiratory hygiene technology to expand access to its products.
Midea Group completed its acquisition of a controlling stake in Esaote, an Italian medical imaging company, bringing it into Midea Healthcare while Esaote continues to operate independently. Midea plans to support Esaote’s growth with investment in research and development, operations, and manufacturing, while providing access to its technology and international distribution resources.
Evident completed its acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The deal expands Evident’s life science imaging portfolio and strengthens its capabilities in high-speed, high-content 3D imaging for research, pharma, and biotech applications.
Surmodics acquired the business of Alta Biomed to expand its portfolio of hemocompatible and biocompatible surface technologies, including the proprietary PzF thin-film surface modification technology. The deal also adds specialized analytical testing capabilities for blood- and tissue-contacting medical devices at Alta Biomed’s Carlsbad, California facility.
Banner Capital announced it formed Seaway Group and entered into a definitive agreement to acquire Seaway Plastics Engineering, MME Group, and Wright Engineered Plastics. The transaction is expected to close in Q4 2026, with Seventeen Capital co-investing and Ron Labrum to serve as Executive Chairman upon closing.
Leica Biosystems, a Danaher company, completed its acquisition of StatLab Medical Products, a provider of pre-analytical consumables and equipment for pathology labs. The deal expands Leica’s end-to-end anatomic and digital pathology ecosystem, supporting workflows from specimen preparation through staining, digital imaging and AI-enabled diagnosis.
RS2 Healthcare Partners announced the completion of its investment in KMM Group and confirmed the appointment of J. Mark King as President and CEO. The release reiterates that KMM is a Hatboro, Pennsylvania-based precision contract manufacturer focused on complex medical device components and highlights RS2’s decision to rebrand and concentrate on healthcare investing.
Command Medical Products, an Argosy Healthcare Partners portfolio company, acquired Injection Moulding & Tooling Services S.A. (IMATS), a Costa Rica-based provider of injection molding and tooling services. The acquisition expands Command’s medical device manufacturing value chain, adds injection molding/tooling expertise, and establishes a third manufacturing site in Costa Rica.
1317234 B.C. Ltd. (“234 B.C.”) and RTRS Technologies Inc. (“RTRS”) entered into a definitive merger agreement to execute a reverse takeover that will list the combined business on the TSX Venture Exchange. Concurrently, the transaction includes a best-efforts private placement raising gross proceeds of not less than $6.85 million via subscription receipts, with Haywood Securities acting as lead agent and sole bookrunner.
Graham Partners’ portfolio company Velosity acquired Lucid Labs, a founder-owned product design, engineering, and prototyping provider serving MedTech OEMs. The deal is intended to expand Velosity’s engineering and innovation capabilities so it can support customers across the full product lifecycle, from early concept development and rapid prototyping through full-scale manufacturing and commercialization.
Enovis entered a binding offer to acquire eCential Robotics for an upfront enterprise value of €155 million, with approximately €176 million in cash consideration and up to €35 million in contingent milestone payments. The proposed acquisition adds eCential’s orthopedic surgical robotics, navigation technology, engineering expertise, and intellectual property to Enovis’ ASTRA platform; it is expected to close by year-end 2026, subject to required processes and regulatory approvals.
Stryker has signed a definitive agreement to acquire ZuriMED, a privately held medical technology company that developed the FiberLocker System for rotator cuff augmentation. The acquisition is intended to strengthen Stryker’s shoulder portfolio and support specialists across sports medicine and shoulder arthroplasty.
Kedaara Capital announced a USD 200 million strategic investment in Tynor Orthotics Private Limited, an Indian orthopaedic supports, mobility aids, and rehabilitation brand. The investment is intended to help deepen Tynor’s orthopaedic-focused wellness platform, expand reach in India and international markets, and support manufacturing and growth initiatives alongside promoters, management, and strategic partner Thuasne.
RPC announced the acquisition of the Peracidin product line from Angelini Pharma. The deal expands RPC’s portfolio of peroxyacetic/peracetic acid (PAA) sterilants used for dialysis, water treatment, and life science applications.
Mitsui Chemicals has completed its previously announced acquisition of Ultradent Products, Inc. to strengthen and grow its oral care business in the United States and expand its global dental materials platform. The company expects post-merger integration to drive cross-selling, innovation, and operating synergies.
Teledyne Technologies Incorporated entered into a definitive agreement to acquire Varex Imaging Corporation for $18.90 per share in cash. The transaction is valued at approximately $1.1 billion (including Varex equity awards and net debt) and is expected to close in early 2027, subject to regulatory approvals and Varex stockholder approval.
MCM Capital Partners has acquired Octex, a Sarasota, Florida-based ISO 13485-certified custom injection molder specializing in highly engineered thermoplastic components for medical device, life sciences, and industrial customers. The deal will provide Octex with additional capital to invest in business development, deepen its commercial infrastructure, and pursue strategic acquisitions to expand technical capabilities and customer relationships.
Currier Plastics, a life sciences contract development and manufacturing provider, completed its strategic acquisition of Sage Product Development. Sage is an engineering, design, and development provider that helps medical device companies take products from concept to commercialization, including contract manufacturing support.
P&F Products & Features GmbH announced the acquisition of AVVie GmbH. The deal adds AVVie’s AngelValve Augmentation System, a transcatheter solution for mitral regurgitation, to P&F’s next-generation structural heart valve portfolio.
MiMedx Group (MIMEDX) has entered into a definitive merger agreement to acquire Sanara MedTech for an enterprise value of approximately $350 million. Under the terms, MIMEDX will buy all outstanding Sanara shares for $33.00 in cash and 0.4735 shares of MIMEDX stock per share, expected to close by year-end subject to approvals and customary conditions.
RS2 Healthcare Partners completed an investment in KMM Group, a vertically integrated precision contract manufacturer serving the medical device industry. In connection with the investment, KMM appointed J. Mark King as President and Chief Executive Officer, while co-founders John Shegda and Eric Wilhelm took on technology and business transformation leadership roles.
Numantec, a global developer, manufacturer, and distributor of infusion medical devices, has entered into a definitive agreement for Goldman Sachs Alternatives’ private equity business to acquire a majority stake. The deal will be purchased from White Bridge Investments and other existing shareholders, with completion expected in Q4 2026 subject to regulatory approvals.
Gentherm (NASDAQ: THRM) has acquired Innovative Medical Equipment, LLC (IME), a Cleveland-area provider of the ThermaZone non-opioid thermal therapy device. The deal is intended to strengthen Gentherm’s Medical business by expanding its medical product portfolio, technology platform, and customer channels.
DePuy Synthes, the orthopedics division of Johnson & Johnson MedTech, acquired Expanding Innovations, Inc., a commercial-stage medical technology company focused on expandable interbody cage systems for spine surgery. The acquisition adds proprietary non-screw-based expandable cage technology to strengthen DePuy Synthes’ spine implant portfolio in the lumbar fusion market.
LianMedical (formerly LianBio) announced the completion of its previously announced merger between LianBio and LianMedical. Under the approved plan of merger, LianMedical merged with and into LianBio, and LianBio continued as the surviving company, with the company changing its name to LianMedical effective upon completion.
Axel Johnson Inc. (AJI) has closed the acquisition of Fort Wayne Metals Research Products (“Fort Wayne Metals,” with its subsidiaries). AJI bought 100% of Fort Wayne Metals from the Glaze family of companies and will keep the business headquartered in Fort Wayne, Indiana.
Leica Biosystems, a Danaher company, signed a definitive agreement to acquire StatLab Medical Products. StatLab is currently owned by Linden Capital Partners and Audax Private Equity, and the transaction is subject to customary closing conditions. Financial terms were not disclosed and the deal was expected to close by the end of 2026.
Steel Partners Holdings L.P. offered to acquire 100% of InMode Ltd. for $16.75 per share in cash, representing a 20% premium to InMode’s “unaffected” share price of $13.95. The offer also allows existing shareholders to roll over up to 40% of their equity into the post-transaction company.
Azenta has completed the sale of its B Medical Systems business to Thelema S.à r.l., closing the transaction on July 1, 2026 after all required conditions were satisfied. Azenta sold B Medical Systems for a fixed $63 million in cash, with $35 million financed through a short-term secured vendor loan provided by an Azenta subsidiary to Thelema.
Pacira BioSciences has agreed to divest its iovera° business to Zimmer Biomet for up to $140 million, consisting of $70 million upfront plus up to an additional $70 million in revenue-based milestone payments. The iovera° system is an FDA-cleared, drug-free medical device that relieves pain through cryoneurolysis.
Gainline Capital Partners’ portfolio company, M&M International, acquired KC Tech. The companies produce complementary precision-engineered stainless-steel tubing for the medical device market, and the deal expands M&M’s manufacturing capabilities and broadens its product portfolio, particularly with larger-diameter tubing. Financial terms were not disclosed.
ALR Technologies entered into a letter of intent to acquire 100% of CGM Medical Technology Singapore and to acquire certain assets of CGM Medical Technology Shenzhen. The deal values CGM Medical Singapore at a total purchase consideration including 200 million ordinary shares and $45 million, with additional contingent earn-out payments tied to free cash flow. ALR Technologies plans to use the acquired technology and licenses to build a manufacturing facility in the Johor-Singapore Special Economic Zone and expects to sign definitive agreements by late July 2026 (Singapore) and late August 2026 (Shenzhen).
InMode said its board received an unsolicited proposal from M.N. Business Strategy to acquire all outstanding ordinary shares not already owned by M.N. Business Strategy and its affiliates. The proposed merger would value the shares at $16.20 per share in cash, and InMode has formed a special committee of independent directors to evaluate the offer.
Advanced Sterilization Products (ASP), part of Fortive’s Infection Prevention group, acquired a majority share of UV Smart, a European leader in UV-C high level disinfection technology. The acquisition is intended to expand ASP’s infection-prevention clinical solutions portfolio and accelerate global adoption of UV Smart’s disinfection products across Europe and North America.
Spring Loaded Technology, a Canadian orthopedic bracing and mobility solutions company, announced a strategic investment from Plaza Capital to support its next phase of growth. The funding is intended to accelerate international expansion (including the United States and Europe), further R&D, and continued advancement of evidence-based mobility solutions.
CVC Catalyst III agreed to acquire a majority stake in WillowWood Holdings Inc., with CVC Catalyst becoming the majority investor alongside Blue Sea Capital, the Arbogast family, and WillowWood management (who will reinvest). The parties expect closing in the third quarter of 2026, subject to regulatory approvals, and plan to use the partnership to accelerate product innovation and international expansion—especially in Europe.
Spectrum Vascular, backed by SK Capital Partners, announced it has acquired Piccolo Medical, a San Francisco-based developer of catheter guidance technologies. The deal will integrate Piccolo’s 510(k)-cleared real-time catheter navigation and location products with Spectrum’s existing vascular access portfolio to accelerate commercialization and support a next-generation guided vascular access standard of care.
Galmed Pharmaceuticals entered into a definitive agreement to acquire Colospan, a commercial-stage colorectal surgery medical device company, positioning Galmed as a GI-focused medtech and biopharmaceutical platform. Colospan’s CG-100 intraluminal bypass device is CE marked under the EU MDR and has an active U.S. pivotal IDE program, while Galmed has restructured acquisition terms and consummated the deal after the announcement of revised anti-dilutive payment and earnout provisions.
Lineus Medical, developer of the SafeBreak Vascular breakaway IV device, completed a strategic recapitalization with KMF Investments. The transaction, finalized at the start of 2026, establishes KMF as a stable financial backer and provides resources to accelerate SafeBreak Vascular adoption and growth in the United States.
ResMed completed its acquisition of Noctrix Health, a medical device company developing wearable therapeutics for chronic neurological disorders. The deal expands ResMed’s clinical sleep health portfolio with Noctrix’s Nidra Tonic Motor Activation (TOMAC) therapy for moderate-to-severe Restless Legs Syndrome (RLS), with Noctrix becoming a wholly owned subsidiary. The acquisition was previously announced as a definitive merger agreement to acquire Noctrix for $340 million, expected to close on or around June 1, 2026.
Johnson & Johnson acquired Atraverse Medical, strengthening its J&J MedTech cardiac electrophysiology portfolio. The acquisition follows the May 15, 2026 close and is referenced in connection with medtech founder John Slump’s subsequent launch of Metis MedTech.
Olympus signed a definitive agreement to acquire BioProtect for $270 million to expand its urology and oncology technology portfolio for prostate cancer care. The deal is expected to close by the end of Q2 2026, subject to customary closing conditions, with portions of the purchase price held in escrow tied to uninterrupted operation.
AP Technologies announced the acquisition of Blueacre Technology, a Dundalk, Ireland-based specialist in laser micromachining and nitinol processing for the medical device industry. The deal expands AP Technologies’ vertically integrated catheter platform by adding nitinol and precision laser processing capabilities and establishes AP Technologies’ first European operation in Ireland.
Atreon Orthopedics and RenovoDerm have merged to form Atreon Orthopedics, Inc., combining synthetic biomaterial technologies for tissue repair and remodeling. The combined company aims to scale its Autobiologic platform technology across orthopedic, trauma, sports medicine, reconstructive, foot and ankle, and complex wound applications.
Endologix, a privately held medical device company, announced it will acquire the Pounce Thrombectomy System from Surmodics. The FDA-cleared, fully mechanical peripheral thrombectomy platform is intended to complement Endologix’s existing vascular intervention portfolio and expand the continuum of care for patients with peripheral vascular disease.
Everis Medical, a Kalamazoo, Michigan-based medical device company focused on otolaryngology and airway management, announced the acquisition of Hood Laboratories. The deal expands Everis’ portfolio of ENT, airway, and thoracic devices and establishes a meaningful entry into airway management.
BellaMia Technologies and Dominion Aesthetic Technologies completed a strategic merger valued at $200 million, combining their laser and robotic medical aesthetics technologies. The merged company will operate under the BellaMia Technologies name with Janet Campbell as CEO, aiming to expand commercial reach and accelerate product development across body contouring and skin rejuvenation.
Stryker completed its acquisition of Amplitude Vascular Systems, a privately held medical device company developing a next-generation intravascular lithotripsy (IVL) platform for calcified peripheral arterial disease (PAD). The deal was announced April 13, 2026 and closed May 7, 2026; financial terms were not disclosed in the MedDeviceGuide account, though other sources cite a value of up to $835 million.
Full Export
Get the full acquisitions list for this page as CSV + XLSX.
Find buyers actively acquiring medical devices companies.
Recent deals highlight portfolio expansion across orthopedic/shoulder systems, structural heart valve augmentation, spine implant technology, infusion medical devices, and thermal therapy devices.
Large medtech strategics (for example Stryker, Teledyne Technologies, Gentherm, DePuy Synthes) and medical-device-focused investors/private equity (for example MCM Capital Partners, GTCR, Inverness Graham Investments) appear alongside manufacturing and development service providers.
Yes. Multiple transactions are described as subject to customary regulatory approvals and other closing conditions (and, where applicable, stockholder approval).
The page shows recent activity in the United States and internationally, including Austria, Italy, Israel, and China.